HNSP was founded in 2000 and is a publicly-traded company. We engage in development, manufacturing and marketing of both APls and drug products. We have more than 10 management members with oversea doctor degree and also oversea experience in R&D, manufacture and/or registration. HNSP enjoys a strong team of regulatory registration, and also a China-based sales force of over 400 agents. With excellent know-how in peptide chemistry, HNSP is a leader in the field of peptide manufacture in China.
Most of our facilities were built based on the EU and US CGMP standards.
HNSP has been inspected respectively by USFDA and (Italy) AIFA and the GMP status was considered acceptable and spoken highly of.
Our Thymalfasin API and FDF has also been approved by (Italy) AIFA.We are open to discuss any forms of collaborations.

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Primary business activity


Contact information




View All Contact Info

Top Products

Aciclovir for injection (0.25g)

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Adenosine cyclophosphate for injection (20mg)

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Azithromycin for injection (0.5g)

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Categories affiliated with Hainan Shuangcheng Pharmaceuticals Co., Ltd.